GU Cancers 2024 | VISION: safety analysis of 177Lu-PSMA-617 in mCRPC

Kim Chi, MD, BC Cancer Vancouver Centre, Vancouver, Canada, delves into findings from a safety analysis of the Phase III VISION trial (NCT03511664) of 177Lu-PSMA-617, a radioligand therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC). The investigational therapy was very efficacious, especially in patients who have progressed on androgen receptor pathway inhibition (ARPI) or docetaxel. Increasing the number of cycles did not increase toxicity and whilst there were adverse effects such as dry mouth, some were attributed to ascertainment bias. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.